MapLight Therapeutics, Inc. MPLT Preclinical Program — Research And Development Expense

Other segment segments

Similar metrics at other companies

LBR

LBRXPreclinical — Direct Research And Development Expenses

$32.25K-93.0%

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

LBR

LBRXPreclinical And Other Direct Expenses — Direct Research And Development Expenses

$501K—

Questions, answered.

What is MapLight Therapeutics, Inc. 's preclinical program — research and development expense?

MapLight Therapeutics, Inc. (MPLT) reported preclinical program — research and development expense of $5.52M in Q1 2026.

How has MapLight Therapeutics, Inc. 's preclinical program — research and development expense changed year-over-year?

MapLight Therapeutics, Inc. 's preclinical program — research and development expense decreased by 9.2% year-over-year, from $6.08M to $5.52M.

What does preclinical program — research and development expense mean?

This metric represents the total operating costs directly attributable to the research and development activities within the company's preclinical-stage pipeline. It captures expenditures related to early-stage drug discovery, laboratory testing, and initial feasibility studies before a candidate enters formal clinical trials. Monitoring this expense provides insight into the company's commitment to innovation and the pace at which it advances its early-stage therapeutic portfolio.